We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Journal of Comparative Effectiveness Research
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Priority Paper Evaluation

Prevention of hepatitis E: another step forward

    Amit Goel

    Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow 226014, India

    Search for more papers by this author

    &
    Rakesh Aggarwal

    † Author for correspondence

    Search for more papers by this author

    Email the corresponding author at aggarwal.ra@gmail.com

    Published Online:16 Dec 2010https://doi.org/10.2217/fmb.10.151

    Abstract

    Zhu F-C, Zhang J, Zhang X-F et al.: Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, Phase 3 trial. Lancet 376, 895–902 (2010).

    Hepatitis E virus (HEV) is frequently implicated in cases with acute viral hepatitis, particularly in developing countries. The infection, transmitted mainly by the fecal–oral route, is generally self-limited. A few affected individuals develop fulminant hepatic failure, a serious condition that is frequently fatal without liver transplantation. This outcome is particularly common when the infection occurs in pregnant women. A vaccine that contains a recombinant truncated capsid protein of HEV produced in an insect cell system has already been shown to be effective in preventing hepatitis E, at least in young men. However, it is not yet available on the market. In the evaluated article, Zhu et al. report the results of a large field trial of another vaccine against hepatitis E that contains a shorter part of the viral capsid protein, produced in Escherichia coli and adsorbed on alum. This trial, which included a large number of subjects of either gender aged 18–65 years, found this newer vaccine as safe and highly effective in preventing clinical disease caused by infection with HEV belonging to the genotype from which the vaccine was derived as well as another genotype. This study should prove to be a major stepping stone in our fight against this important disease pathogen.

    Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

    Bibliography

    • 1  Zhu F-C, Zhang J, Zhang X-F et al.: Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, Phase 3 trial. Lancet376,895–902 (2010).▪▪ The paper under review.Crossref, Medline, CAS, Google Scholar
    • 2  Kamar N, Selves J, Mansuy JM et al.: Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N. Engl. J. Med.358,811–817 (2008).▪▪ First reported case series of chronic hepatitis E virus (HEV) infection; the patients were receiving immunosuppression.Crossref, Medline, CAS, Google Scholar
    • 3  Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S: Persistent carriage of hepatitis E virus in patients with HIV infection. N. Engl. J. Med.361,1025–1027 (2009).Crossref, Medline, CAS, Google Scholar
    • 4  Ollier L, Tieulie N, Sanderson F et al.: Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab. Ann. Intern. Med.150,430–431 (2009).Crossref, Medline, Google Scholar
    • 5  Tam AW, Smith MM, Guerra ME et al.: Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology185,120–131 (1991).▪ First report on cloning and full sequencing of HEV genome, with identification of viral genes.Crossref, Medline, CAS, Google Scholar
    • 6  Lu L, Li C, Hagedorn CH: Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis. Rev. Med. Virol.16,5–36 (2006).▪ A report on classification of HEV isolates into various genotypes and their geographic and host species relationship.Crossref, Medline, CAS, Google Scholar
    • 7  Aggarwal R, Naik S: Epidemiology of hepatitis E: current status. J. Gastroenterol. Hepatol.24,1484–1493 (2009).▪▪ A recent review on epidemiology and clinical features of HEV infection.Crossref, Medline, Google Scholar
    • 8  Vishwanathan R: Infectious hepatitis in Delhi (1955–1956): a critical study: epidemiology. Indian J. Med. Res.45(Suppl. 1),1–29 (1957).▪▪ A report on the epidemiological findings during the first well-studied epidemic of HEV-related hepatitis.Google Scholar
    • 9  Mansuy JM, Abravanel F, Miedouge M et al.: Acute hepatitis E in south-west France over a 5-year period. J. Clin. Virol.44,74–77 (2009).▪ A large case-series of hepatitis E cases in a low-endemic region.Crossref, Medline, CAS, Google Scholar
    • 10  Dalton HR, Thurairajah PH, Fellows HJ et al.: Autochthonous hepatitis E in southwest England. J. Viral Hepat.14,304–309 (2007).Crossref, Medline, CAS, Google Scholar
    • 11  Khuroo MS, Teli MR, Skidmore S, Sofi MA, Khuroo MI: Incidence and severity of viral hepatitis in pregnancy. Am. J. Med.70,252–255 (1981).Crossref, Medline, CAS, Google Scholar
    • 12  Kumar A, Aggarwal R, Naik SR, Saraswat V, Ghoshal UC, Naik S.: Hepatitis E virus is responsible for decompensation of chronic liver disease in an endemic region. Indian J. Gastroenterol.23,59–62 (2004).Medline, Google Scholar
    • 13  Tam A, White R, Yarbough PO et al.: In vitro infection and replication of hepatitis E virus in primary cynomolgus macaque hepatocytes. Virology238,94–102 (1997).Crossref, Medline, CAS, Google Scholar
    • 14  Aggarwal R, Shahid J: Hepatitis E vaccine. Hepatol. Int.2,308–315 (2008).Crossref, Medline, Google Scholar
    • 15  Purdy MA, McCaustland KA, Krawczynski K, Spelbring J, Reyes GR, Bradley DW: Preliminary evidence that a trpE–HEV fusion protein protects cynomolgus macaques against challenge with wild-type hepatitis E virus (HEV). J. Med. Virol.41,90–94 (1993).Crossref, Medline, CAS, Google Scholar
    • 16  Tsarev SA, Tsareva TS, Emerson SU et al.: Successful passive and active immunization of cynomolgus monkeys against hepatitis E. Proc. Natl Acad. Sci. USA91,10198–10202 (1994).Crossref, Medline, CAS, Google Scholar
    • 17  Tsarev SA, Tsareva TS, Emerson SU et al.: Recombinant vaccine against hepatitis E: dose response and protection against heterologous challenge. Vaccine15,1834–1838 (1997).Crossref, Medline, CAS, Google Scholar
    • 18  Purcell RH, Nguyen H, Shapiro M et al.: Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine. Vaccine21,2607–2615 (2003).Crossref, Medline, CAS, Google Scholar
    • 19  Shrestha MP, Scott RM, Joshi DM et al.: Safety and efficacy of a recombinant hepatitis E vaccine. N. Engl. J. Med.356,895–903 (2007).▪▪ Report of a human clinical trial with the first HEV vaccine.Crossref, Medline, CAS, Google Scholar
    • 20  Li SW, Zhang J, Li YM et al.: A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine23,2893–2901 (2005).Crossref, Medline, CAS, Google Scholar
    • 21  Zhang J, Liu CB, Li RC et al.: Randomized-controlled Phase II clinical trial of a bacterially expressed recombinant hepatitis E vaccine. Vaccine27,1869–1874 (2009).▪ A smaller trial with the vaccine used in the paper under review.Crossref, Medline, CAS, Google Scholar